Found 427 clinical trials
-
Phase 3 trial
-
Accepting pediatric ages
-
Accepting adults
-
Oncology
-
Currently Recruiting
A Randomized Phase III Trial of Adjuvant Therapy Comparing Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel with or without Carboplatin for Node-Positive or High-Risk Node-Negative Triple-Negative Invasive Breast Cancer
A Randomized Phase III Trial of Adjuvant Therapy Comparing Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel with or without Carboplatin for Node-Positive or High-Risk Node-Negative
- 66 views
- 03 Dec, 2020
- 1 location
-
Multi-country trial
-
Phase 3 trial
-
Accepting pediatric ages
-
Accepting adults
-
Currently Recruiting
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of Niraparib Maintenance Treatment in Patients with Advanced Ovarian Cancer Following Response on Front-Line Platinum-Based Chemotherapy
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of Niraparib Maintenance Treatment in Patients with Advanced Ovarian Cancer Following Response on Front-Line Platinum-Based Chemotherapy
- 1940 views
- 23 Nov, 2020
- 106 locations
-
Phase 3 trial
-
Accepting pediatric ages
-
Currently Recruiting
GOG 0258: A Randomized Phase III Trial of Cisplatin and Tumor Volume Directed Irradiation Followed by Carboplatin and Paclitaxel vs. Carboplatin and Paclitaxel for Optimally Debulked, Advanced Endometrial Carcinoma.
GOG 0258: A Randomized Phase III Trial of Cisplatin and Tumor Volume Directed Irradiation Followed by Carboplatin and Paclitaxel vs. Carboplatin and Paclitaxel for Optimally Debulked, Advanced
- 176 views
- 08 Nov, 2020
- 1 location
-
Phase 2 trial
-
Accepting pediatric ages
-
Accepting adults
-
Oncology
-
Currently Recruiting
A Randomized, Double-blind, Placebo-Controlled, Phase 2 Study to Assess the Efficacy and Safety of Farletuzumab (MORAb-003) in Combination with Carboplatin plus Paclitaxel or Carboplatin plus Pegylated Liposomal Doxorubicin (PLD) in Subjects with Low CA125 Platinum-Sensitive Ovarian Cancer
A Randomized, Double-blind, Placebo-Controlled, Phase 2 Study to Assess the Efficacy and Safety of Farletuzumab (MORAb-003) in Combination with Carboplatin plus Paclitaxel or Carboplatin plus
- 88 views
- 23 Nov, 2020
- 1 location
-
Phase 3 trial
-
Accepting pediatric ages
-
Accepting adults
-
Currently Recruiting
A Phase III, Open-Label, Randomized Study of MPDL3280A (Anti-PD-L1 Antibody) In Combination With Carboplatin + Paclitaxel With or Without Bevacizumab Compared With Carboplatin + Paclitaxel + Bevacizumab In Chemotherapy-Naïve Patients With Stage IV Non-Squamous Non-Small Cell Lung Cancer (NSCLC)
A Phase III, Open-Label, Randomized Study of MPDL3280A (Anti-PD-L1 Antibody) In Combination With Carboplatin + Paclitaxel With or Without Bevacizumab Compared With Carboplatin + Paclitaxel
- 144 views
- 08 Nov, 2020
- 1 location
-
Phase 2 trial
-
Accepting pediatric ages
-
Currently Recruiting
GOG-0264: A Randomized Phase II Trial of Paclitaxel and Carboplatin vs. Bleomycin, Etoposide, and Cisplatin for Newly Diagnosed Advanced State and Recurrent Chemonaive Sex Cord-Stromal Tumors of the Ovary
GOG-0264: A Randomized Phase II Trial of Paclitaxel and Carboplatin vs. Bleomycin, Etoposide, and Cisplatin for Newly Diagnosed Advanced State and Recurrent Chemonaive Sex Cord-Stromal Tumors of the
- 544 views
- 08 Nov, 2020
- 1 location
-
Phase 3 trial
-
Accepting pediatric ages
-
Currently Recruiting
GOG 0213: A Phase III, Randomized, Controlled Clinical Trial of Carboplatin and Paclitaxel Alone or in Combination with Bevacizumab Followed by Bevacizumab and Secondary Cytoreductive Surgery in Platinum-Sensitive, Recurrent Ovarian, Primary Peritoneal and Fallopian Tube Cancer. NCI-SUPPLIED AGENTS: BEVACIZUMAB.
GOG 0213: A Phase III, Randomized, Controlled Clinical Trial of Carboplatin and Paclitaxel Alone or in Combination with Bevacizumab Followed by Bevacizumab and Secondary Cytoreductive Surgery in
- 614 views
- 08 Nov, 2020
- 1 location
-
Phase 3 trial
-
Accepting pediatric ages
-
Currently Recruiting
A Phase 3 Randomized, Placebo-controlled Trial of Carboplatin and Paclitaxel With or Without the Poly ADP-ribose Polymerase (PARP) Inhibitor Veliparib (ABT-888) in Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Metastatic or Locally Advanced Unresectable Breast Cancer Gene (BRCA)-Associated Breast Cancer
A Phase 3 Randomized, Placebo-controlled Trial of Carboplatin and Paclitaxel With or Without the Poly ADP-ribose Polymerase (PARP) Inhibitor Veliparib (ABT-888) in Human Epidermal Growth Factor
- 74 views
- 08 Nov, 2020
- 1 location
-
Phase 3 trial
-
Accepting pediatric ages
-
Accepting adults
-
Oncology
-
Currently Recruiting
A Phase 3 Placebo-Controlled Study of Carboplatin/Paclitaxel With or Without Concurrent and Continuation Maintenance Veliparib (PARP inhibitor) in Subjects with Previously Untreated Stages III or IV High-Grade Serous Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
A Phase 3 Placebo-Controlled Study of Carboplatin/Paclitaxel With or Without Concurrent and Continuation Maintenance Veliparib (PARP inhibitor) in Subjects with Previously Untreated Stages III or
- 856 views
- 23 Nov, 2020
- 1 location
-
Unknown Phase
-
Accepting pediatric ages
-
Accepting adults
-
Oncology
-
Currently Recruiting
A Biomarker-Driven Master Protocol for Previously Treated Squamous Cell Lung Cancer (Screening Step) Lung-MAP Study
A Biomarker-Driven Master Protocol for Previously Treated Squamous Cell Lung Cancer (Screening Step) Lung-MAP Study
- 28 views
- 23 Nov, 2020
- 1 location